LIVE HEALTHIER LONGER

Biophytis®

A pioneering biotechnology company focused on developing transformative therapies that impact longevity

Founded on pioneering science from researchers at SORBONNE UNIVERSITÉ

Forward Looking Statements

This presentation contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as **«outlook », «believes», «expects», «potential», «continues», «may», «will», «should», «could», «seeks», «predicts», «intends», «trends», «plans», «estimates», «anticipates» or the negative version of these words or other comparable words.** These forward-looking statements include statements regarding Biophytis' anticipated timing for its various BIO101 (20-hydroxyecdysone) clinical trials and expectations regarding commercialization. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable.

However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties including, without limitation, delays in patient recruitment or retention, interruptions in sourcing or supply chain, its ability to obtain the necessary regulatory authorizations, COVID-19-related delays, and the impact of the current pandemic on the Company's clinical trials. The forward-looking statements contained in this presentation are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis.

Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please refer to the «Risk Factors» section of the Company's 2023 Full Year Financial Report available on BIOPHYTIS website *(www.biophytis.com)* and to the risks discussed in the Company's registration statement on Form F-1 and other reports filed with the Securities and Exchange Commission (the "SEC"). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

Biophytis®

Mission & Vision

Advancing Longevity

by discovering new targets and drug candidates addressing fundamental needs in human aging



Our leadership team has a proven track record across drug discovery, development, and commercialization

Management Committee

Stanislas Veillet
Chief Executive Officer

Edouard Bieth
Chief Strategy Officer

Pierre Dilda
Chief Scientific Officer

Christophe Courtillat
Chief Financial Officer (Ad Interim)

Chiara Baccelli
Chief Pharmaceutical Officer

Waly Dioh
Chief Clinical Operations Officer

Jean Mariani
Chief Medical Officer

Cumulative years of experience

176y in R&D

126y in BioPharma

Nb of IND **20+**

Nb of Rx products registreted / commercialized **40+**

Broad Experience in BioPharma and beyond

AstraZeneca

Bristol Myers Squibb

MAYOLY
Votre santé nous tient à cœur

SERVIER

ucb

DANONE

Takeda

MONSANTO

Our 3 Strategic R&D programs

Our Longevity Research Platform

A unique platform combining several technologies accelerated by AI for the discovery of new drug candidates impacting longevity

- Exploration and identification of the **fundamental mechanisms of aging** to develop 21st-century therapeutic solutions
- A platform leveraging **different synergistic technology modalities**
- **Systematic use of AI** through our partnership with Lynx Analytics.

BIO101 in Sarcopenia

The world's most advanced clinical program in sarcopenia

- **In sarcopenia, no approved treatment exists**, and it is estimated that up to 1 out of 4 people aged over 60 worldwide are affected [(1)]
- The phase 2 clinical trial demonstrated **BIO101's efficacy in improving mobility** in patients with sarcopenia [(2)]
- For the first time, a phase 3 study in sarcopenia is planned in Asia and Europe

BIO101 in Obesity

A unique program targeting mobility in patients suffering from obesity

- **Obesity is booming, affecting 1 billion patients globally [(3)], and 96% report experiencing mobility issues** [(4)]
- **A phase 2 clinical trial** is planned in Europe and Brazil to test **BIO101's efficacy in combination with GLP1**.
- **A License agreement** in LATAM has been signed with Blanver Pharma and the trial has obtained public **co-funding** in Brazil.

(1) Yuan 2023, Epidemiology of Sarcopenia, Metabolism
(2) Journal of Cachexia, Sarcopenia and Muscle, 2025; 16:e13750
(3) World Health Organization 2022
(4) Valenzuela et al. BMC Musculoskeletal Disorders (2020) 21:200

Biophytis®

Our Longevity Research Platform

BIO101 in Sarcopenia

BIO101 in Obesity

Biophytis

Our research explores and identifies the fundamental mechanisms of aging to develop new therapeutic solutions…

Our Longevity Research Platform

…in partnership with the most prestigious research academies in France

SCIENCES SORBONNE UNIVERSITÉ · cnrs · Inserm · AFM TELETHON · INSTITUT DE LA VISION · INSTITUT DE MYOLOGIE INNOVER POUR GUÉRIR



Most common diseases among elderly people

Our research has developed unique R&D capabilities

Our Longevity Research Platform

Target ID & validation

Exploration and identification of the fundamental mechanisms of aging [1]

Biology of Aging: Targeting pathways like Mas-related G protein-coupled receptor (MasR), which is part of the renin-angiotensin system, Peroxisome proliferator-activated receptor pathway and key inflammatory and angiogenic signaling routes, including NF-κB and AP-1 transcription factors.

Technology Assessment and Lead ID

Expertise across discovery and development with a unique tech-forward approach integrating **various drug Modalities:**

Small Molecules
Precision-targeted, scalable, orally available



Other technologies
Programmable, tissue-selective, adapted for complex targets

Screening and Candidate selection

We use 2 types of screening Methods :

Focused Screening:
Selection and testing of a smaller group of coumpounds believed to have activity based on prior knowledge, lietrature or known chemical classes

Virtual Screening via AI-Driven Discovery:
Advanced analytics to reveal new lead candidates

(1) The Hallmarks of Aging, Cell 153, June 6, 2013

Biophytis®

Our Longevity Research Platform

BIO101 in Sarcopenia

BIO101 in Obesity

BIO101 : Our drug candidate is an oral small molecule potential for best in class acting on the root cause of muscle wasting

First in class molecule

- Validated mechanism of action
- Activation of MAS receptor (protective arm of the renin-angiotensin system)
- Regulation of smooth, cardiac and skeletal muscle metabolism

Ease of administration

- API manufactured at industrial scale
- Advanced CMC
- Oral capsules adapted to obese patients



Excellent safety profile

- More than 275 patients exposed to BIO101 in clinical trials
- No major adverse event observed

Focused development program for improving mobility

US IND granted & Rock-solid IP

- 14 patent families granted in key countries
- Running until 2044
- 90% of world Pharma market covered



Sarcopenia, an exploding market with no therapeutic solution as of today

BIO101 in Sarcopenia

Sarcopenia is a disorder defined consensually by several consortia (FNIH, EWGSOP, SDOC and ESCEO), **characterized by progressive and generalized loss of skeletal muscle mass and strength**, reduction of physical performance **associated with** an increased risk of adverse events such as **disability, poor quality of life and death**

up to 1/4 people aged > 60 are affected(1)

+178%	x2,3	-6y
Risk of Falls(2)	Risk of death(2)	Life expectancy(3)

No pharmacological treatment has yet been approved, **only limited options** exist

Vitamin/dietary supplements

It may improve muscle strength and muscle mass
No Clinical evidence

Off label Drugs

The use of off label drugs is based on empiric practice
Data on sub population of large trials exist but not demonstrated

(1) Yuan 2023, Epidemiology of Sarcopenia, Metabolism
(2) Landi F, Liperoti R, Russo A, et al. Sarcopenia as a risk factor for falls in elderly individuals. Results for the ilSIRENTE Study. *Cl Nut*. 2012;31(5):652-658.
(3) Brown JC, Harhay MO, Harhay MN. Sarcopenia and mortality among a population-based sample of community-dwelling older adults. *J Cachexia Sarcopenia Muscle*. 2016;7(3):290-298

BIO101 is the most advanced drug candidate in sarcopenia

BIO101 in Sarcopenia

Drug	Company	Technology	Main Endpoints	Safety & Side effects	Administration route	Status
BIO101 (20 hydroxyecdysone)	Biophytis	**MAS Receptor activator**	**High Dose showed promising results on gait speed (Phase 2)**	**Excellent tolerability profile and no serious adverse events**	**oral**	**Phase 3 to start (SARA)**
STOP Bimugrumab, Trevogrumab, MYMD-1, Enobosarm						**Development in sarcopenia halted after Phase 2**
RJx-01	Rejuvenate Biomed	Combo Metformin + Galantamine	In a Phase 1b clinical trial, RJx - 01 showed promising results in improving muscle strength.	Generally safe and well tolerated with no reported treatment-related serious or severe adverse events	oral	Phase 1b finalized
OC-514	ONCOCROSS	Small molecule AI-driven	Preclinical proof of concept	Favorable safety profile and pharmacokinetic parameters	oral	Phase 1 to start

Fielding 2025 et al. Journal of Cachexia, Sarcopenia and Muscle, 2025; 16:e13750,
https://www.rejuvenatebiomed.com/en/news/positive-results-phase-1b-trial-in-sarcopenia,
https://www.clinicaltrialsarena.com/news/oncocross-phase-i-sarcopenia-trial/

In Phase 2, BIO101 improved mobility of patients suffering from sarcopenia

BIO101 in Sarcopenia

SARA



Journal of Cachexia, Sarcopenia and Muscle



	1 Sarcopenic obesity	2 Slow walkers (Gait speed ≤ 0,8 m/s)	3 Mobility frailty (chair stand ≤2)	Total SARA-INT population
Gait speed (m/s) 400MWT Change from Baseline *PP analysis*	**+0.06**	**+0.07**	**+0,09**	**+0,09**
% Gait Speed improvement	**+7%**	**+8%**	**+11%**	**+11%**
P value	0,0037	0,0154	0,0037	0,008

BIO101 350mg BID *versus* placebo :
Gait Speed Improvement

+11%

Fielding 2025 et al. Journal of Cachexia, Sarcopenia and Muscle, 2025; 16:e13750

We aim at conducting the first Phase 3 ever in sarcopenia to confirm the clinical efficacy of BIO101 in a larger population

SARA 31 : The first Phase 3 ever in sarcopenia

A phase 3 trial to evaluate efficacy & safety of BIO-101 versus placebo in older patients suffering from sarcopenia: an interventional, randomized double-blind placebo-controlled, clinical trial

Population:
932 sarcopenic seniors treated for at least 12 months with BIO101 350 mg bid versus placebo

Primary endpoint:
Time (in days) to the first occurrence of **Major Mobility Disability (MMD) assessed by the inability to complete the 400-meter walk test within 15 minutes**

Secondary endpoints: Gait speed 4-m from SPPB, Handgrip Strength (HGS), Sarcopenia – QoL (SarQol) Patient-Reported Outcome



***Pr Fielding**, TOP Voice in sarcopenia*

«In the SARA-INT trial, BIO101 showed a promising improvement of the 400MWT gait speed, a critical outcome for seniors at risk of mobility disability. These important findings reinforce the need to move to a confirmatory Phase 3 clinical program in older sarcopenic patients»

Targeted Indication

Treatment of severe sarcopenia in older patients (≥65 years) who are at risk of mobility disability

Partneship Formation in Asia

融汇仁和 R.Lifenergy

- **Creation of a joint venture in Hong Kong**
- **Injection of US$20 million by the consortium of investors**
- **Start of clinical operations in early 2026**

The vast majority of patients suffering from Obesity have mobility issues

BIO101 in Obesity

World Health Organization

Global Number of Obese patients among the adult population



96% of obese patients have **impaired muscle strength**(2)

(1) https://www.morganstanley.com/insights/articles/weight-loss-medication-market-unstoppable-growth
(2) Valenzuela et al. BMC Musculoskeletal Disorders (2020) 21:200

A unique program targeting mobility in patients suffering from obesity

BIO101 in Obesity

Strong Proof of concept (1)





A Phase 2 targeting muscle quality in obesity

Sample size : 164 patients

Target population:

Obese patients BMI ≥30 or overweight (BMI ≥27) with one or more weight-related sequalae (e.g. dysglycemia, hypertension) who will start treatment with semaglutide (a GLP-1 agonist).

1st Endpoint

Muscle strength *(knee extension determined by dynamometry)*

2nd Endpoints

6 minutes walking test

5 time Sit-to-Stand test

Hand grip test

Body composition (lean body & fat mass)

Pr Cornier, President of Obesity Society US

« It is critical for us to study the safety and efficacy of BIO101 designed to reduce the risk of muscle mass loss »

Partnership established

License agreement in LATAM signed with BLANVER PHARMA

BLANVER

Valued up to 108m€

Up to 50% of the local clinical operations in Brazil financed by public funding

EMBRAPII

(1) : Serova et al., 2022; Foucault et al., 2012; Data on file, Biophytis

Major upcoming milestones on our 3 R&D programs

Our Longevity Research Platform

ACHIEVED

- ✓ Partnership signed with LYNX Analytics in AI
- ✓ Protocol to identify new candidates in sarcopenia finalized
- ✓ New therapeutic targets exploration ongoing

TO COME

- Additional modalities to be included
- Partnership with Academic Research Centers in Aging / Longevity

BIO101 in Sarcopenia

ACHIEVED

- ✓ Trial readiness : work preparation with CROs
- ✓ CTA granted by EMA
- ✓ BIOPHYTIS and a Consortium of Investors including RONGHUI RENHE Life Technology Join Forces to Finance and Launch First-Ever Phase 3 Trial in Sarcopenia

TO COME

- Partnership Formation
- IND submission in China (NMPA)
- IND submission in Japan (PMDA)
- Study Start up
- First patient inclusion

BIO101 in Obesity

ACHIEVED

- ✓ BIO101 + GLP-1 animal studies results
- ✓ BLANVER License agreement signed
- ✓ IND granted by FDA
- ✓ CTA Granted by EMA
- ✓ Public funding obtained in Brazil
- ✓ Clinical Centers identified and selected in Europe, Brazil and US

TO COME

- IND submission in Brazil (ANVISA)
- Study Start up
- First patient inclusion

Our Pipeline:
Transformative therapies that impact longevity

Strategic Programs

Candidate	Indication	Program
BIO101	**Sarcopenia**	**SARA**
BIO101	**Obesity**	**OBA**
Target Discovery	**Multiple Targets**	

other projects

BIO101	*Covid 19*	*COVA*
BIO101	*DMD*	*MYODA*
BIO203	*Dry AMD*	
BIO203	*Stargardt disease*	



Financial data

Shareholding structure



Noteworthy investors: Atlas, BlackRock and Armistice
Number of shares: 29,766,653 (September 30, 2025)

Key financials

Listing Euronext (ALBPS) and US market (OTC)

- **Cash position:** €78K (December 31st, 2024)
- **Additional cash in FY2025 :**
  - €2.5m in January 2025 (cash contribution)
  - €2.6m in March 2025 (private placement)
- **Debt conversion:** €4m commitment from BlackRock and Atlas

Analyst Coverage

Kepler Cheuvreux — Nicolas Pauillac

AM invest — Jamila El Bougrini

Biophytis®

Mission & Vision



Our Longevity Research Platform

A unique platform combining several technologies accelerated by AI for the discovery of new drug candidates impacting longevity

BIO101 in Sarcopenia

The world's most advanced clinical program in sarcopenia

BIO101 in Obesity

A unique program targeting mobility in patients suffering from obesity